LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

Search

Twist Bioscience Corp

Closed

SectorHealthcare

52.2 -4.76

Overview

Share price change

24h

Current

Min

51.66

Max

54.05

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

-5.32% downside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

409M

3B

Previous open

56.96

Previous close

52.2

News Sentiment

By Acuity

50%

50%

162 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

19 Feb 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

19 Feb 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19 Feb 2026, 23:39 UTC

Acquisitions, Mergers, Takeovers

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19 Feb 2026, 23:38 UTC

Earnings

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19 Feb 2026, 23:38 UTC

Earnings

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19 Feb 2026, 23:38 UTC

Earnings

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19 Feb 2026, 23:37 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19 Feb 2026, 23:34 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19 Feb 2026, 23:34 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19 Feb 2026, 23:33 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19 Feb 2026, 23:33 UTC

Earnings

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19 Feb 2026, 22:13 UTC

Market Talk

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19 Feb 2026, 22:08 UTC

Earnings

Fairfax Financial 4Q Rev $8.11B >FFH.T

19 Feb 2026, 22:07 UTC

Earnings

Eldorado Gold 4Q EPS $1.19 >ELD.T

19 Feb 2026, 22:06 UTC

Earnings

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19 Feb 2026, 22:05 UTC

Earnings

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19 Feb 2026, 22:05 UTC

Earnings

Eldorado Gold 4Q Rev $577.2M >ELD.T

19 Feb 2026, 22:04 UTC

Earnings

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19 Feb 2026, 22:04 UTC

Earnings

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19 Feb 2026, 21:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

19 Feb 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19 Feb 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

19 Feb 2026, 21:43 UTC

Earnings

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19 Feb 2026, 21:42 UTC

Acquisitions, Mergers, Takeovers

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19 Feb 2026, 21:42 UTC

Earnings

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19 Feb 2026, 21:41 UTC

Earnings

Correct: St Barbara 1H Net Loss A$249,000

19 Feb 2026, 21:40 UTC

Earnings

St Barbara 1H Net Loss A$249 Million

19 Feb 2026, 21:39 UTC

Earnings

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19 Feb 2026, 21:37 UTC

Earnings

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19 Feb 2026, 21:37 UTC

Earnings

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

-5.32% downside

12 Months Forecast

Average 52 USD  -5.32%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

162 / 351 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat